Rabies shot reveals immune secrets in CAR-T cancer survivors
NCT ID NCT04410900
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed phase 1 trial gave the rabies vaccine to 49 people who had previously received CAR-T therapy for B-cell cancers, along with healthy volunteers for comparison. The goal was to see if their immune systems could mount a normal response to a vaccine. By measuring rabies antibodies in the blood, researchers hope to learn how well the immune system recovers after CAR-T treatment, which could guide future infection prevention.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Rabies vaccine (Imovax Rabies)
- What this could lead to
- If successful, this study could help doctors understand how well the immune system works after CAR-T therapy, leading to better infection prevention strategies for these patients.
- What could go wrong
- This is a small, early-phase study that only measures immune response to a vaccine, not a treatment itself. Results may not apply to all patients or predict real-world infection risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
49 people
The number who actually took part.
- Started
-
Aug 2020
- Finished
-
Aug 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * CARTx RECIPIENTS: Patients must be capable of understanding and providing a written informed consent * CARTx RECIPIENTS: Patients must be 18 years of age or older, of any gender, race or ethnicity * CARTx RECIPIENTS: Patients must have had relapse-free survival for \>= 6 months after receiving CARTx for B-cell malignancies * CARTx RECIPIENTS: Platelet count \> 30,000 / mm\^3 * HEALTHY CONTROLS: Patients must be capable of understanding and providing a written informed consent * HEALTHY CONTROLS: Patients must be 18 years of age or older, of any gender, race or ethnicity Exclusion Criteria: * CARTx RECIPIENTS: Patients who have received a hematopoietic cell transplant after CARTx * CARTx RECIPIENTS: Previously received 1 or more rabies vaccines prior to the first vaccine visit * CARTx RECIPIENTS: Patients who have received lymphodepleting therapies after CARTx and within the past 6 months * CARTx RECIPIENTS: Patients with signs or symptoms of active infection * CARTx RECIPIENTS: Patients who are pregnant or breastfeeding * CARTx RECIPIENTS: Patients with previous known allergies to any component of the vaccine * CARTx RECIPIENTS: Patients who have previously experienced a reaction to any vaccine that required medical attention * CARTx RECIPIENTS: Study participants who report a severe adverse event following the first rabies vaccine will not be eligible for a second dose * CARTx RECIPIENTS: Receiving corticosteroids \> 0.5 mg/kg/day prednisone equivalence in the 7 days prior to first or second vaccination * HEALTHY CONTROLS: Previously received 1 or more rabies vaccines * HEALTHY CONTROLS: Chronic illness * HEALTHY CONTROLS: Signs or symptoms of active infection * HEALTHY CONTROLS: Pregnant or breastfeeding * HEALTHY CONTROLS: Patients with previous known allergies to any component of the vaccine * HEALTHY CONTROLS: Previous reaction to a vaccine that required medical attention
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-cell neoplasm are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.